Recent Updates — NWBO

On October 26, 2026, Northwest Biotherapeutics entered into a Commercial Loan Agreement with Streeterville Capital for $5,505,000. The loan carries an 8% annual interest rate and includes a 10% original issue discount. Repayment begins on June 26, 2027, with 14 equal monthly installments following an eight-month deferral period. Proceeds are designated for ongoing business operations. Northwest Biotherapeutics operates in the biotechnology industry, focusing on cancer immunotherapy.

Northwest Biotherapeutics entered into a $4.9 million convertible Promissory Note financing with YA II PN, Ltd., managed by Yorkville Advisors Global, LP. The 12-month note carries no interest but includes a five percent original issue discount and is convertible at the holder's option at a small discount to market price. Proceeds are for general corporate purposes. Concurrently, the company executed a new standby equity subscription agreement allowing Yorkville to subscribe for up to $50 million in common shares after the note is repaid or converted, replacing a prior cancelled agreement. Yorkville also received warrants to purchase up to $2 million of shares at $0.205 per share. Northwest Biotherapeutics operates in the biotechnology industry, developing personalized immune therapies for solid tumor cancers.

Northwest Biotherapeutics addressed rumors alleging that the Medicines and Healthcare Products Regulatory Agency (MHRA) rejected its Marketing Authorization Application (MAA) for DCVax-L for glioblastoma (GBM). The MHRA confirmed the application remains under initial regulatory review and has not been refused, withdrawn, or appealed. The company refutes the rumors and suggests they may be part of stock manipulation following the presentation of encouraging Phase 3 trial data at the British Neuro-Oncology Society Annual Meeting. Northwest Biotherapeutics is a biotechnology company developing cancer immunotherapies.